BioSpace News Archive

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 64,000 shares of the company’s common stock to two new employees.

Arcturus Therapeutics Holdings Inc., a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that the Company will participate in the following investor conferences.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in September.

Shattuck Labs, Inc. announced that company management will participate in two investor conferences in September 2022.

Iterum Therapeutics plc announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

Alpha Tau Medical Ltd. announced that Peter Melnyk, a member of its board of directors, has resigned from the Company’s Board of Directors in order to assume the full-time position of Alpha Tau’s Chief Commercial Officer.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C. Wainwright 24th Annual Global Investor Conference.

Liminal BioSciences Inc. announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market that the Company’s application to transfer its common shares from The Nasdaq Global Market to The Nasdaq Capital Market, as allowed under Listing Rule 5810, had been approved.

Senseonics Holdings, Inc. announced its Chief Financial Officer, Nick Tressler, is transitioning from his position, effective September 1, 2022.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences.